

Innovative therapies for skin diseases

Maximising the value of your clinical and preclinical assets for patients suffering from a dermatological condition



Our aim

We are looking for partnering opportunities on new assets in clinical or preclinical development stages that can be useful for the treatment of dermatological diseases.

The assets should involve any therapeutic modality such as small molecules, biologics, or advanced therapies:

- Targeting immuno-inflammatory pathways with rationale for dermatological indications such as atopic dermatitis, hidradenitis suppurativa, alopecia areata, and vitiligo, or
- Suitable for non-melanoma skin cancer (basal and squamous cell carcinoma, and cutaneous T cell lymphoma), or rare dermatological indications (e.g., epidermolysis bullosa, pemphigus vulgaris, bullous pemphigoid, ...)
- For pre-clinical assets, compelling *in vitro* and *in vivo* evidence of efficacy will be highly valuable

Who is this for

This call is addressed to scientists affiliated to start-ups, biotechs, pharmaceutical companies, universities, and research centres all over the world.

Collaboration framework

- Submitted proposals may be eligible for
 - A clinical or preclinical development partnership or collaboration
 - Further characterisation of the asset by Almirall in a pre-agreed panel of relevant assays and *in vivo* models for dermatological diseases
- An Almirall designated contact person will help you on answering your questions
- The potential to establish a long-term business partnership

Collaboration process

- Proposal submission
 - The first step is for you to create an account in [AlmirallShare Innovation platform](#) which is a secure site to store and manage your proposals
 - The submission period is from July 20th, 2022 to October 31st, 2022
 - Please include an outline of your proposal (max. 300 words) and a description of the type of asset, its pharmacological, pharmacokinetic and safety profile, as well as its current development stage (max 3 pages)
 - All the initial information provided under the proposal should be non-confidential. In case you would like to share information under a non-disclosure agreement, please contact us at shared.innovation@almirall.com

Submissions will be handled following all applicable local compliance rules

- Proposal evaluation and selection
 - A team of Almirall's scientific experts will evaluate your proposal as soon as it is received
 - You will receive in writing Almirall's decision regarding your proposal within 8 -10 weeks after submission
 - If your proposal has been selected, a member of the AlmirallShare Team will contact you to initiate a partnership agreement that will reflect a collaborative proposal, including eventual experimental activities, and/or a business proposal according to current asset's development phase

Join us in our journey
Almirall, Science and you
AlmirallShare Team